Cyanotech Stock Forecast, Price & News

+0.05 (+1.62 %)
(As of 04/16/2021 04:00 PM ET)
Today's Range
Now: $3.14
50-Day Range
MA: $3.57
52-Week Range
Now: $3.14
Volume34,892 shs
Average Volume253,480 shs
Market Capitalization$19.14 million
P/E Ratio31.40
Dividend YieldN/A
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. The company's products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human nutraceutical and functional food ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye and joint health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. Cyanotech Corporation sells its products as packaged consumer products through distributors, retailers, and online channels, and direct to consumers, as well as in bulk form to manufacturers, formulators, and distributors. The company was founded in 1983 and is headquartered in Kailua-Kona, Hawaii.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Current SymbolNASDAQ:CYAN
Year FoundedN/A



Sales & Book Value

Annual Sales$31.90 million
Cash Flow$0.45 per share
Book Value$2.67 per share


Net Income$390,000.00


Market Cap$19.14 million
Next Earnings Date6/22/2021 (Estimated)
OptionableNot Optionable


Cyanotech Co. (NASDAQ:CYAN) Short Interest Update
April 13, 2021 |
Why Cyanotech's Stock is Trading Higher Today
March 29, 2021 |
Cyanotech Co. (NASDAQ:CYAN) Sees Large Drop in Short Interest
March 27, 2021 |
See More Headlines


Overall MarketRank

0.61 out of 5 stars

Medical Sector

1368th out of 2,024 stocks

Medicinals & Botanicals Industry

17th out of 33 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
+0.05 (+1.62 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CYAN News and Ratings via Email

Sign-up to receive the latest news and ratings for CYAN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cyanotech (NASDAQ:CYAN) Frequently Asked Questions

What stocks does MarketBeat like better than Cyanotech?

Wall Street analysts have given Cyanotech a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cyanotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cyanotech?

Cyanotech saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 264,600 shares, an increase of 11,927.3% from the March 15th total of 2,200 shares. Based on an average daily volume of 271,300 shares, the short-interest ratio is presently 1.0 days. Approximately 5.8% of the company's stock are sold short.
View Cyanotech's Short Interest

When is Cyanotech's next earnings date?

Cyanotech is scheduled to release its next quarterly earnings announcement on Tuesday, June 22nd 2021.
View our earnings forecast for Cyanotech

How were Cyanotech's earnings last quarter?

Cyanotech Co. (NASDAQ:CYAN) issued its earnings results on Thursday, February, 11th. The biotechnology company reported $0.13 earnings per share for the quarter. The biotechnology company had revenue of $6.99 million for the quarter. Cyanotech had a net margin of 1.82% and a trailing twelve-month return on equity of 3.67%.
View Cyanotech's earnings history

How has Cyanotech's stock been impacted by Coronavirus (COVID-19)?

Cyanotech's stock was trading at $1.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CYAN stock has increased by 57.8% and is now trading at $3.14.
View which stocks have been most impacted by COVID-19

Who are Cyanotech's key executives?

Cyanotech's management team includes the following people:
  • Dr. Gerald R. Cysewski Ph.D., Co-Founder, CEO & Vice Chairman (Age 72, Pay $151.06k)
  • Mr. Glenn D. Jensen, VP of Operations (Age 63, Pay $177.42k)
  • Ms. Felicia I. Ladin, CFO & VP of Fin. & Admin. and Treasurer (Age 49)
  • Mr. Charles J. Hartmann, Sr. Sales & Marketing Director
  • Ms. Amy Beth Nordin, VP of HR & Corp. Sec. (Age 53)

What is Brent D. Bailey's approval rating as Cyanotech's CEO?

4 employees have rated Cyanotech CEO Brent D. Bailey on Brent D. Bailey has an approval rating of 68% among Cyanotech's employees.

Who are some of Cyanotech's key competitors?

What other stocks do shareholders of Cyanotech own?

What is Cyanotech's stock symbol?

Cyanotech trades on the NASDAQ under the ticker symbol "CYAN."

How do I buy shares of Cyanotech?

Shares of CYAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyanotech's stock price today?

One share of CYAN stock can currently be purchased for approximately $3.14.

How much money does Cyanotech make?

Cyanotech has a market capitalization of $19.14 million and generates $31.90 million in revenue each year.

How many employees does Cyanotech have?

Cyanotech employs 95 workers across the globe.

What is Cyanotech's official website?

The official website for Cyanotech is

Where are Cyanotech's headquarters?

Cyanotech is headquartered at 73-4460 QUEEN KAAHUMANU HWY SUITE 102, KAILUA KONA HI, 96740.

How can I contact Cyanotech?

Cyanotech's mailing address is 73-4460 QUEEN KAAHUMANU HWY SUITE 102, KAILUA KONA HI, 96740. The biotechnology company can be reached via phone at 808-326-1353 or via email at [email protected]

This page was last updated on 4/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.